Dr. Jon Wagg Will Present on Improving Clinical Research Productivity
MOUNTAIN VIEW, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Pharsight
Corporation (Nasdaq: PHST), a leading provider of software, strategic
consulting, and regulatory services for optimizing clinical drug
development, today announced that Jonathan Kuwabara-Wagg, MD, Ph.D., Senior
Scientist, will lead a lecture on improving clinical research planning on
February 26, 2008 at 14:00 pm local time at the eClinical Forum conference
in Geneva, Switzerland.
Dr. Wagg will present on the following topics:
-- FDA and the Critical Path in the context of the pharmaceutical R&D
-- The Innovative Medicines Initiative
-- Model Based Drug Development -- What is it and how can it improve R&D
-- Need for IT Infrastructure to Support Modeling and Simulation
For more information on the conference please go to the following address: http://www.eclinicalforum.com/.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.
|SOURCE Pharsight Corporation|
Copyright©2008 PR Newswire.
All rights reserved